Connexin biology is a rapidly evolving field that plays a crucial role in intercellular communication through gap junctions and hemichannels. These connexin-mediated pathways are essential for maintaining cellular homeostasis and have been implicated in a variety of diseases, including cancer, congenital cataracts, depression, hereditary deafness, and congenital heart disease. Recent studies have highlighted the dual role of connexins, encompassing both channel-dependent and independent functions, which are pivotal in disease pathogenesis. Despite the progress, there remain significant gaps in understanding the full spectrum of connexin functions and their potential as biomarkers for disease diagnosis and prognosis. Current research is focused on developing molecular approaches such as mimetic peptides, connexin inhibitors, and antibodies to target these proteins effectively. However, the translation of these findings into clinical practice is still in its infancy, necessitating further investigation into the mechanisms and therapeutic potential of connexin-targeting strategies.
This Research Topic aims to explore the latest advancements in the development of connexin-based biomarkers and connexin-targeting agents within clinical research settings. The primary objectives include understanding the application of these biomarkers and agents across various disease contexts and elucidating their potential diagnostic and therapeutic implications. Key questions to be addressed involve the efficacy of connexin-targeting agents in preclinical and clinical studies, the molecular mechanisms underlying these agents, and the impact of connexin mutations on disease susceptibility and progression.
To gather further insights in the realm of connexin biology and its clinical applications, we welcome Brief Research Report, Clinical Trial, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Study Protocol, and Systematic Review articles addressing, but not limited to, the following themes:
• Exploration of connexin-based biomarkers for disease diagnosis and prognosis.
• Evaluation of connexin-targeting agents in preclinical and clinical studies.
• Molecular mechanisms underlying connexin-targeting agents.
• Impact of connexin mutations on disease susceptibility and progression.
• Development of novel molecular strategies targeting connexins for therapeutic interventions.
• Connexin dysfunction in ocular diseases and potential therapeutic interventions.
• Connexin-based approaches for regenerative medicine and tissue engineering.
Keywords:
Connexins, Diseases, Therapy, Diagnostic, Gap Junctions
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Connexin biology is a rapidly evolving field that plays a crucial role in intercellular communication through gap junctions and hemichannels. These connexin-mediated pathways are essential for maintaining cellular homeostasis and have been implicated in a variety of diseases, including cancer, congenital cataracts, depression, hereditary deafness, and congenital heart disease. Recent studies have highlighted the dual role of connexins, encompassing both channel-dependent and independent functions, which are pivotal in disease pathogenesis. Despite the progress, there remain significant gaps in understanding the full spectrum of connexin functions and their potential as biomarkers for disease diagnosis and prognosis. Current research is focused on developing molecular approaches such as mimetic peptides, connexin inhibitors, and antibodies to target these proteins effectively. However, the translation of these findings into clinical practice is still in its infancy, necessitating further investigation into the mechanisms and therapeutic potential of connexin-targeting strategies.
This Research Topic aims to explore the latest advancements in the development of connexin-based biomarkers and connexin-targeting agents within clinical research settings. The primary objectives include understanding the application of these biomarkers and agents across various disease contexts and elucidating their potential diagnostic and therapeutic implications. Key questions to be addressed involve the efficacy of connexin-targeting agents in preclinical and clinical studies, the molecular mechanisms underlying these agents, and the impact of connexin mutations on disease susceptibility and progression.
To gather further insights in the realm of connexin biology and its clinical applications, we welcome Brief Research Report, Clinical Trial, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Study Protocol, and Systematic Review articles addressing, but not limited to, the following themes:
• Exploration of connexin-based biomarkers for disease diagnosis and prognosis.
• Evaluation of connexin-targeting agents in preclinical and clinical studies.
• Molecular mechanisms underlying connexin-targeting agents.
• Impact of connexin mutations on disease susceptibility and progression.
• Development of novel molecular strategies targeting connexins for therapeutic interventions.
• Connexin dysfunction in ocular diseases and potential therapeutic interventions.
• Connexin-based approaches for regenerative medicine and tissue engineering.
Keywords:
Connexins, Diseases, Therapy, Diagnostic, Gap Junctions
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.